Welcome to the IAM Patent 1000 2015 – The World’s Leading Patent Professionals, the fourth edition of our unique guide to leading private practice patent professionals and firms in the world’s key jurisdictions. There is no other publication like the IAM Patent 1000 - a one-stop resource exclusively focused on identifying best-in-class patent prosecution, licensing and litigation practitioners on a global basis, as well as expert witnesses in the United States.
Over the course of five months, our dedicated IAM research team based in London and Hong Kong conducted detailed interviews with hundreds of private practice lawyers and attorneys, as well as the users of their services, in countries across the world, in order to identify the practitioners and practices that are instructed by clients when only the best will do. In the United States, we also asked interviewees to name the expert witnesses they turn to when they need world-class input on both damages and technical issues. The firms and individuals listed on the following pages are the results of that research.
All those listed in the IAM Patent 1000 are included because we received substantial positive feedback about them from multiple sources. We do not claim that we have managed to find every top name in every jurisdiction covered; but we are confident that we have included the vast majority, and that everybody who is listed fully merits their inclusion. A detailed methodology which explains the research process, as well as how our researchers decided who should finally be listed, can be found here.
In addition to the listings and editorial, you will find further biographical information on some of the individuals featured at the end of each country section, and on some of the selected firms at the end of each regional chapter. All those who were selected for inclusion in the IAM Patent 1000 were offered the opportunity to publish this information for a fee – some decided that they wished to, while others declined. Inclusion in the editorial is in no way linked to this: the research was conducted entirely independent of any commercial considerations.
Search IAM Patent 1000
ENSafrica is Africa’s largest law firm, with more than 600 professional advisers and offices in South Africa (Alexandra, Cape Town, Durban, Johannesburg, Mitchells Plain and Stellenbosch) as well as Burundi (Bujumbura), Mauritius (Port Louis), Namibia (Windhoek and Swakopmund), Rwanda (Kigali) and Uganda (Kampala). The firm has a breadth and depth of expertise that spans all areas of law, tax, forensics and intellectual property. ENSafrica’s IP department incorporates a patent group comprising patent attorneys, many of whom are recognised as leaders in their field both in Africa and internationally. The patent group offers a full suite of patent services across a number of ...
Cravath, Swaine & Moore LLP
David R Marriott is a partner in Cravath’s litigation department. Mr Marriott has tried, argued and litigated IP and other complex commercial matters in both state and federal courts across the country. His practice also encompasses numerous forms of alternative dispute resolution. Mr Marriott has represented a number of major pharmaceutical and technology companies, including Mylan, IBM, Novartis, Qualcomm, Noven Pharmaceuticals, Bristol-Myers Squibb and AT&T. Mr Marriott recently represented Mylan in a patent infringement suit over Teva Pharmaceuticals’ development of a generic form of Mylan’s respiratory drug Perforomist®. Following a seven-day bench trial, the court ...
Five years into its bailout programme, the Greek economy still has a long way to go. Far-left party Syriza gained a parliamentary majority in early 2015 on an anti-austerity ticket and vowed to renegotiate with the nation’s creditors for better terms; but whether this will be possible remains to be seen. In the meantime, industry continues to suffer. Little R&D activity takes place in Greece, so much of the patent work comes from foreign clients, especially multinational pharmaceutical companies. The country’s ongoing financial woes mean that generic drugs are increasingly popular – a trend that has prompted a rise in litigation and nullity actions. Litigation outside the ...
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email